- Home
- WFG vs GH Comparison
WFG vs GH Comparison
Compare WFG & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WFG
- GH
- Stock Information
- Founded
- WFG 1955
- GH 2011
- Country
- WFG Canada
- GH United States
- Employees
- WFG N/A
- GH 2021
- Industry
- WFG
- GH Medical Specialities
- Sector
- WFG
- GH Health Care
- Exchange
- WFG Nasdaq
- GH Nasdaq
- Market Cap
- WFG 6.0B
- GH 4.9B
- IPO Year
- WFG N/A
- GH 2018
- Fundamental
- Price
- WFG $73.71
- GH $40.62
- Analyst Decision
- WFG Buy
- GH Strong Buy
- Analyst Count
- WFG 3
- GH 21
- Target Price
- WFG $105.00
- GH $52.81
- AVG Volume (30 Days)
- WFG 143.0K
- GH 2.3M
- Earning Date
- WFG 07-23-2025
- GH 04-30-2025
- Dividend Yield
- WFG 1.74%
- GH N/A
- EPS Growth
- WFG N/A
- GH N/A
- EPS
- WFG N/A
- GH N/A
- Revenue
- WFG $6,006,000,000.00
- GH $773,996,000.00
- Revenue This Year
- WFG $1.36
- GH $23.05
- Revenue Next Year
- WFG $8.10
- GH $21.40
- P/E Ratio
- WFG $2,915.47
- GH N/A
- Revenue Growth
- WFG N/A
- GH 28.20
- 52 Week Low
- WFG $69.48
- GH $20.14
- 52 Week High
- WFG $102.40
- GH $52.92
- Technical
- Relative Strength Index (RSI)
- WFG 47.30
- GH 48.45
- Support Level
- WFG $72.66
- GH $37.73
- Resistance Level
- WFG $74.97
- GH $39.63
- Average True Range (ATR)
- WFG 1.55
- GH 1.60
- MACD
- WFG -0.08
- GH -0.01
- Stochastic Oscillator
- WFG 26.31
- GH 60.00
About WFG West Fraser Timber Co. Ltd Common stock
West Fraser Timber is a softwood lumber company that also produces wood panels and pulp products. The company produces its wood products globally, with lumber mills in British Columbia, Alberta, Europe, and the Southeastern United States. Following its acquisition of Norbord in 2021, West Fraser is now one of the largest oriented strand board producers in the world.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.